SR 140333 prevents potentiation by citric acid of plasma exudation induced by histamine in airways.

Article Details

Citation
Copy to clipboard

Biyah K, Molimard M, Emonds-Alt X, Advenier C

SR 140333 prevents potentiation by citric acid of plasma exudation induced by histamine in airways.

Eur J Pharmacol. 1996 Jul 25;308(3):325-8.

PubMed ID
8858307 [ View in PubMed
]
Abstract

We here report a model of potentiation by citric acid of airway microvascular leakage induced by histamine and its modification by the tachykinin NK1 and NK2 receptor antagonists, SR 140333 ((S)1-{2-[3-(3,4-dichlorophenyl)-1-(3-iso-propoxyphenylacetyl)p iperidin- 3-yl]ethyl}-phenyl-1-azoniabicyclo[2.2.2]octane, chloride) and SR 48968 (S)-N-methyl-N-[4-(4-acetyl-amino-4-phenylpiperidino)-2-(3,4- dichlorophenyl-butyl]benzamide. Guinea-pigs exposed to an acrosol of citric acid 0.4 M for 1 h developed 24 h later a hyperresponsiveness to histamine-induced microvascular leakage measured by Evans blue dye extravasation. SR 140333, but not SR 48968 (1 mg kg-1 given each once 30 min before citric acid exposure), prevented this potentiation. These results provide further evidence of the role of tachykinin and tachykinin NK1 receptor stimulation on airway hyperresponsiveness and its neurogenic inflammatory component.

DrugBank Data that Cites this Article

Drugs